reading telehealth threads from 2024 and half of it aged badly
Long-ish post, sorry. tl;dr at the bottom.
I have been tracking state board against eGFR for 35 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here.
Caveats up front: one person, one lab, one assay, no control, and I changed my training in the middle of it, which was stupid.
tl;dr: probably real, definitely smaller than the threads imply, and not worth reorganising your week around.
best — the order this archive was captured in
Disagree. What you are describing is consistent with state board, not with what you concluded.
Disagree.
Yes, exactly this, and it is the bit that took me 82 weeks to accept.
shortage list status is API source, check the actual list
Asked 5 compounders about API source. One told me, one dodged, one said they cannot say. The answer is the signal.
API source questions are on-topic and compounders dodging them is newsworthy
Strongly agree. API source transparency matters.
This is an urgent-care question wearing a forum question's clothes. Please contact a clinician rather than waiting for replies.
API transparency is the question that separates good compounders from sketchy ones
Yeah, 503A and 503B are different regulatory animals.
Did they tell you their API source or dodge the question?
Not convinced. The evidence does not support that reading.
You have restated the marketing copy. What is the actual substance here.
This is correct. The shortage list does expire and the rules change.
Yeah, 503A and 503B are different regulatory animals.
This is correct. The shortage list does expire and the rules change.
Are we talking 503A or 503B?
the shortage list is temporary, it ends and compounding becomes illegal again
This is correct.
Adding to this: state board is doing more work than the comment implies.
That is net peptide content, not purity. Different number, different meaning.
503B compounding is different from 503A, different rules, different legality
503B compounding is different from 503A, different rules, different legality
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
Every time this gets posted it hits the front page and every time someone has to re-explain it.
You have restated the marketing copy. What is the actual substance here.
the shortage list is temporary, it ends and compounding becomes illegal again
503B compounding is different from 503A, different rules, different legality
state board rules differ, say which state
state board rules differ, say which state
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
telehealth costs telehealth plus compounding markup, total varies
- 1API transparency is the question that separates good compounders from…7 comments in this branch · started by u/bilal_osei
- 2This is correct. The shortage list does expire and the rules change.7 comments in this branch · started by u/priya_palacios